Manganese oxide nanoparticles as mri contrast agents in tumor multimodal imaging and therapy

88Citations
Citations of this article
87Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Contrast agents (CAs) play a crucial role in high-quality magnetic resonance imaging (MRI) applications. At present, as a result of the Gd-based CAs which are associated with renal fibrosis as well as the inherent dark imaging characteristics of superparamagnetic iron oxide nanoparticles, Mn-based CAs which have a good biocompatibility and bright images are considered ideal for MRI. In addition, manganese oxide nanoparticles (MONs, such as MnO, MnO2,Mn3O4, and MnOx) have attracted attention as T1-weighted magnetic resonance CAs due to the short circulation time of Mn(II) ion chelate and the size-controlled circulation time of colloidal nanoparticles. In this review, recent advances in the use of MONs as MRI contrast agents for tumor detection and diagnosis are reported, as are the advances in in vivo toxicity, distribution and tumor microenvironment-responsive enhanced tumor chemotherapy and radiotherapy as well as photothermal and photodynamic therapies.

Cite

CITATION STYLE

APA

Cai, X., Zhu, Q., Zeng, Y., Zeng, Q., Chen, X., & Zhan, Y. (2019). Manganese oxide nanoparticles as mri contrast agents in tumor multimodal imaging and therapy. International Journal of Nanomedicine. Dove Medical Press Ltd. https://doi.org/10.2147/IJN.S218085

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free